Amgen posted strong earnings beat and has an attractive dividend, and technical chart forecasting positive future performance ...

But this week, the stock jumped again after Amgen issued a strong financial update Tuesday. Its rise helped push up the S&P ...

BofA raised the firm’s price target on Amgen (AMGN) to $275 from $256 and keeps an Underperform rating on the shares. Q4 results were slightly ...

Results include $1.2 billion of sales from rare disease products, driven by TEPEZZA, KRYSTEXXA, UPLIZNA, and TAVNEOS. Earnings reflect acquisition-related costs related to the Horizon acquisition.

Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

The post contains 50 new customer stories, which appear at the beginning of each section of customer lists. The post will be ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...

The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...

The main focus in Teva’s innovative portfolio continues to be neuroscience and immunology, with clinical trials for three key assets underway: olanzapine for treatment of schizophrenia, ...